FDA Class II Recall: BluePoint Laboratories' Haloperidol Decanoate Injection Faces Sterility Concerns
BluePoint Laboratories faces an FDA Class II recall of 14,189 vials of Haloperidol Decanoate Injection, 100 mg/mL, due to bacterial contamination from its manufacturer, Somerset Therapeutics Limited in India. This nationwide recall, D-0368-2025, demands immediate action from procurement and regulatory teams to secure alternative supplies and assess supply chain vulnerabilities for this critical Central Nervous System drug.
FDA Mandates Nationwide Class II Recall of BluePoint Laboratories' Haloperidol Decanoate Injection
The U.S. Food and Drug Administration (FDA) has initiated a Class II recall, designated D-0368-2025, for 14,189 vials of BluePoint Laboratories' Haloperidol Decanoate Injection, 100 mg/mL. This voluntary, firm-initiated recall, reported on April 30, 2025, stems from a critical lack of assurance of sterility, with bacterial contamination specifically detected in some media fill units. The affected product, identified by NDC 68001-581-41 and lot number A240482A with an expiration date of August 31, 2026, was distributed nationwide in the USA by Amerisource Health Services LLC from its Columbus, Ohio facility. For procurement directors, this means an immediate need to quarantine and return all affected stock, incurring logistical costs and potential write-offs. Regulatory affairs heads must ensure compliance with recall procedures and prepare for increased scrutiny on sterility protocols. Supply chain VPs face the challenge of rapidly identifying and qualifying alternative sources to prevent stockouts of this essential Central Nervous System (CNS) medication, which is used as a typical antipsychotic. The Class II classification indicates that while exposure may cause temporary or medically reversible adverse health consequences, the probability of serious adverse health consequences is remote, yet the risk of patient harm from contaminated injectables remains a significant concern for healthcare providers.
Manufacturing Origin and BluePoint's Extensive Pharmaceutical Portfolio
The recalled Haloperidol Decanoate Injection, 100 mg/mL, although marketed by BluePoint Laboratories, was manufactured by Somerset Therapeutics Limited at its facility located at #54/1, Boodhihal Village, Nelamangala, Bangalore - 562123, Karnataka, India. This highlights BluePoint Laboratories' reliance on contract manufacturing organizations (CMOs) in international geographies for key products. BluePoint Laboratories, a U.S.-based manufacturer with a 'low' risk band, maintains a diverse product portfolio spanning multiple therapeutic areas beyond CNS drugs. Their extensive product list includes oncology drugs like Imatinib Mesylate and Cyclophosphamide, cardiovascular medications such as Lisinopril and Metoprolol, and anti-infectives like Ertapenem and Daptomycin. This broad market presence means that any systemic quality issues at a contract manufacturer, particularly concerning sterility, could have wider implications across BluePoint's other injectable or sterile product lines. Business development executives should assess the potential for reputational damage and the need for enhanced due diligence on all third-party manufacturing partners, especially those located in regions with varying regulatory oversight standards. This event underscores the critical importance of robust quality agreements and continuous oversight of overseas manufacturing operations.
Critical Supply Chain Disruptions for Haloperidol Decanoate in the US Market
The recall of 14,189 vials of Haloperidol Decanoate Injection represents a significant disruption to the supply chain for this critical antipsychotic medication across the United States. Haloperidol Decanoate is a typical antipsychotic, vital for managing chronic psychiatric conditions, and its intermittent availability can severely impact patient care and treatment continuity. The nationwide distribution pattern means that healthcare facilities and pharmacies across all states are potentially affected, necessitating widespread inventory checks and product returns. For supply chain VPs, the immediate challenge is to quantify the exact market impact and ensure that replacement stock can be secured without undue delay. The specific NDC (68001-581-41) and dosage (100 mg/mL) are crucial identifiers for managing this shortage. Business development executives may see opportunities for competitors to fill the immediate supply gap, but also a heightened awareness among buyers regarding supplier reliability and quality assurance. Procurement teams must prioritize securing alternative supplies to prevent prolonged shortages, which could lead to adverse patient outcomes and increased operational costs for healthcare systems.
Strategic Sourcing: Identifying Alternative Suppliers for Haloperidol Decanoate
In light of the ongoing recall, procurement directors must swiftly identify and qualify alternative suppliers for Haloperidol Decanoate to maintain continuity of supply. Several companies are known to supply generic Haloperidol Decanoate, offering potential avenues for diversification. These include Aurohealth, Granules India, NorthStar Rx, NURAY CHEMICALS, HEB, Armas Pharmaceuticals, Apotex, and Derma Care Research Labs. This list provides a starting point for immediate outreach and qualification processes. When evaluating these alternatives, supply chain VPs should consider not only product availability and pricing but also the supplier's regulatory history, manufacturing capabilities, and geographic location to mitigate future single-source risks. Qualification timelines for sterile injectable products can be extensive, often requiring facility audits and stability data review, making proactive engagement critical. Regulatory affairs heads must ensure that any new supplier's product meets FDA standards and that all necessary documentation for approval is in place. Prioritizing suppliers with robust quality management systems and a track record of FDA compliance will be paramount to minimize future supply chain vulnerabilities and ensure patient safety.
Regulatory Compliance Implications and Future Outlook for BluePoint Laboratories
The Class II recall of Haloperidol Decanoate Injection places significant regulatory scrutiny on BluePoint Laboratories and its contract manufacturer, Somerset Therapeutics Limited. The 'Ongoing' status of the recall indicates that the FDA expects comprehensive corrective and preventive actions (CAPA) to address the root cause of the bacterial contamination. Regulatory affairs heads at BluePoint must ensure Somerset Therapeutics implements robust sterility assurance measures, including a thorough investigation into the media fill failures and improvements to aseptic processing controls. Failure to adequately address these issues could lead to further regulatory actions, including potential Warning Letters, Import Alerts for the manufacturing facility in India, or even product seizures. For business development executives, this event may impact future market access and partnership opportunities, as buyers will increasingly scrutinize supplier quality and regulatory compliance records. Supply chain VPs must evaluate the long-term viability of their relationship with Somerset Therapeutics and consider strategies for diversifying their manufacturing base to reduce reliance on a single, now compromised, facility. This incident serves as a critical reminder for all stakeholders to maintain rigorous oversight of third-party manufacturing to safeguard product quality and patient safety.